Biotest - Model BT588 -Severe Community Acquired Pneumonia Pipeline

Trimodulin (BT588, predecessor BT086) is a human plasma-derived native polyvalent antibody preparation for intravenous administration. Trimodulin contains immunoglobulins IgM (-23%), IgA (~ 21%) and igG (-56%). Trimodulin mediates its mode of action via three potential mechanisms which are; opsonization of causal pathogens, neutralizing of microbial pathogens and their virulence factors (endo- and exotoxins) and targeting the host inflammatory response (anti-inflammatory properties). Currently, trimodulin is under clinical development for severe community-acquired pneumonia (sCAP). These patients suffer from very severe lung infections, and a high number need life saving measures such as mechanical ventilation. The average mortality rate is between 30% and 50%. which makes sCAP one of the main causes of infection-related death in Europe and the USA.